N/A
N=160
A Clinical Evaluation of PROPEL® Contour Sinus Implant
Chronic Rhinosinusitis (Diagnosis)
Bottom Line
View on ClinicalTrials.gov: NCT04858802 ↗Enrolled (actual)
160
Serious AEs
1.3%
Results posted
Apr 2023
Primary outcome: Primary: Difference in FSO Patency by Blinded Reviewer — 16.54; 12.36 mm^2 — p=0.059
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- PROPEL Contour Sinus Implant (Device); Balloon Sinus Dilation Alone (Procedure)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Intersect ENT
- Primary completion
- Feb 2022
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Difference in FSO Patency by Blinded Reviewer |
16.54; 12.36 | 0.059 |
| SECONDARY FSO Cross-sectional Area Change From Baseline on CT by an Independent, Blinded Reviewer |
2.63; 1.15; 3.20; 5.95 | 0.328 |
| SECONDARY CT Frontal Sinus Outflow Tract (FSOT) Volume by Blinded Reviewer |
383.11; 332.17; 386.86; 414.30 | 0.306 |
| SECONDARY CT FSO Minimum Diameter by Blinded Reviewer |
2.38; 1.89; 2.56; 2.54 | 0.031 sig |
| SECONDARY CT Zinreich's Modified Lund-Mackay Score for the Frontal Sinus by Blinded Reviewer |
1.23; 1.28; 1.22; 1.05 | 0.715 |
| SECONDARY Number of Sinus Sides Requiring Post-operative Intervention by Clinical Investigators |
5; 5; 14; 17; 12; 16 | 1.00 |
| SECONDARY CT Cross-sectional Area of FSO by Blinded Reviewer |
17.72; 17.81 | 0.971 |
| SECONDARY CT Lund-Mackay Score for the Frontal Sinus by Blinded Reviewer |
0.77; 0.77; 0.72; 0.67 | 1.00 |
| SECONDARY CT Lund-Mackay Score for the Frontal Sinus by Clinical Investigators |
0.59; 0.68; 0.53; 0.59 | 0.225 |
| SECONDARY Adhesion/Scarring Grade in the Frontal Recess/FSO by Clinical Investigators |
0.37; 0.41; 0.30; 0.48; 0.21; 0.48 | 0.537 |
| SECONDARY Inflammation Score in the Frontal Recess/FSO by Clinical Investigators |
25.94; 28.85; 19.17; 26.67; 21.97; 28.62 | 0.634 |
| SECONDARY Polypoid Edema in the Frontal Recess/FSO by Clinical Investigators |
0.63; 0.88; 0.53; 0.77; 0.53; 0.80 | 0.063 |
| SECONDARY Adhesion/Scarring Grade in the Ethmoid Sinus by Clinical Investigators |
0.28; 0.30; 0.34; 0.35; 0.26; 0.39 | 0.830 |
| SECONDARY Polyp Grade in the Ethmoid Sinus by Clinical Investigators |
0.29; 0.32; 0.30; 0.34; 0.31; 0.39 | 0.666 |
| SECONDARY CRS Side-specific Symptom Score by Subject |
6.19; 6.25; 4.75; 4.68; 4.42; 4.42 | 0.868 |
| SECONDARY SNOT-22 Score by Subject |
17.84; 17.84 | — |
| SECONDARY RSI Score by Subject |
7.7; 7.7 | — |
| SECONDARY Implant Delivery Success by Clinical Investigators |
80 | — |
Summary
The objective of this study is to evaluate the efficacy of PROPEL Contour placement following an in-office frontal sinus balloon dilation (SBD) in patients with chronic rhinosinusitis (CRS)
Eligibility Criteria
Inclusion Criteria
- Patient is 18 years of age or older.
- Patient is willing and able to comply with protocol requirements.
- Patient has confirmed diagnosis of CRS per International Consensus Statement on Allergy and Rhinology, Rhinosinusitis 2021 (ICAR:RS) guidelines.
- Bilateral disease in the frontal sinuses (Lund-Mackay CT score of ≥1 on each side) on CT scan within 90 days prior to the baseline.
- A successfully completed in-office bilateral balloon dilation of the FSO with no complication on either side that, in the opinion of the clinical investigator is amenable for PROPEL Contour Sinus Implant placement in both FSO
Exclusion Criteria
- Patient has structural obstruction that precludes endoscopic visualization of one or both FSOs prior to implant placement.
- Expanded amount of ethmoid sinonasal polyps extending beyond the middle meatus (grade > 2) unless reduced 30 days prior to the baseline procedure
- Oral-steroid dependent condition such as chronic obstructive pulmonary disease (COPD) or other conditions.
- Known history of allergy or intolerance to corticosteroids or mometasone furoate.
- Patients with a known hypersensitivity to lactide, glycolide or caprolactone copolymers.
- Patients with electronic devices in direct connection to the brain or the nervous system such as implantable neurostimulators (e.g. deep brain stimulation), programmable cerebrospinal fluid (CSF) shunts.
- Patients with monopolar pacemakers (older designs, with lower resistance to interference) or ICD's (implantable cardioverter defibrillator).
- Patients with implantable, body worn devices such as insulin pumps.
- Evidence of purulence coming from paranasal sinuses or ostiomeatal complex.
- Clinical evidence of acute bacterial sinusitis or invasive fungal sinusitis (e.g. bone erosion on prior CT scan, necrotic sinus tissue).
- Active viral illness (e.g., flu, shingles).
- Use of parenteral or injected steroids (e.g. Kenalog) 30 days prior to the baseline procedure.
- Use of oral steroids, budesonide or other sinus steroid irrigations/rinses or drops, nebulized steroids administered nasally 14 days prior to baseline procedure.
Data sourced from ClinicalTrials.gov (NCT04858802). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.